Cryo Immunotherapy Part 2

Part 2 of the lecture about Cryo Immune Therapy given by Dr. Israel  Barken from the Prostate Research and Education Foundation.  Dr. Barken describes Cryo immunotherapy. The reasons why there are no consistent immune response after cryoablation are discussed.  Suggestions for further research to enhance the cryoablation immune activation are brought up, based on pre clinical research on the subject.  This is the second lecture to be followed up by further evidence of the cryo immunology phenomena.

Posted in Cryo Immunotherapy, Cryoablation, Prostate Cancer, Treatments for Prostate Cancer | Leave a comment

Cryo Immunotherapy Part 1

Dr. Barken presents the history of cryoablation and the new developments in the field of immunology which will create enhancement of the Immune effect on metastatic disease in response to cryoablation of local tumor.

Posted in Cryo Immunotherapy, Cryoablation, Immune Therapy, Metastatic Disease, Metastatic Prostate Cancer Disease, Treatments for Prostate Cancer, Vaccine | Leave a comment

Cryoablation Immuno Therapy

Clinical Study Phase I Cryoimmunotherapy against Metastatic prostate Cancer Disease.


Dr. Israel Barken, the Medical Director of the Prostate Cancer Research and Education, presents a clinical study phase I, featuring cryosurgery plus immuno-Modulator – Cyclophosphamide and Anti CTLA 4 Antibodies- Ipilimumab (Yervoy)

Posted in Castration Resistant Prostate Cancer, Clinical Trials, Immune Therapy, Prostate Cancer, Treatments for Prostate Cancer, Vaccine | Leave a comment

Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer

Phase I study approach of priming the immune system with Prostvac vaccination, intensified immunotherapy with Ipilimumab to further enhance the immune response.  This was presented by Hapreet Singh M.D. from the National Cancer Institute.

Genentech video explaining the “Security Checkpoint System” is incorporated in the video presentation above. You can view it separately by clicking on the Video below.

 

Posted in Ask Dr. Barken, Immune Therapy, Metastatic Prostate Cancer Disease, Treatments for Prostate Cancer, Vaccine | Leave a comment

Percentage Involved Core Length and Risk of Recurrence After Radical Prostatectomy

Article: Greatest Percentage Involved Core Length and Risk of Clinically Significant Prostate-Specific Antigen Failure After Radical Prostatectomy.

Author:  Anthony V. D’Amico

Source: Clinical Genitourinary Cancer.  March 5, 2015

Posted in Biopsy, Prognosis, Prostate Cancer, PSA, Survival prostate cancer, Treatments for Prostate Cancer | Leave a comment

Active Surveillance In Intermediate-Risk Prostate Cancer

Active Surveillance In Intermediate-Risk Prostate Cancer Called Into Question.
https://youtu.be/dBk3z2T9KwQ

Dr. Israel Barken brings info about higher risk of cancer specific mortality in the intermediate prostate cancer risk group. The study presentor at the GenitoUrinary Symposium 2015 was Dr. Andrew Loblaw. The study was conducted at the Sunnybrook Health Sciences Center. The risk of prostate cancer-specific death at 15 years was 3.75 times higher for intermediate risk patients compared to patients with low risk patients.

Source: ASCO POST March , 2015

Posted in Active Surveillance, Treatments for Prostate Cancer | Tagged , | 1 Comment

Testosterone and the risk of cancer.

Testosterone and the risk of cancer.


Dr. Israel Barken , the medical director of the prostate cancer research and education foundation PCREF discusses a recent article in the BJU Int. 2015 Feb;115(2):317-21..
Testosterone therapy and cancer risk.
Eisenberg ML1, Li S, Betts P, Herder D, Lamb DJ, Lipshultz LI

Posted in Testosterone | Tagged , , | Leave a comment

Circulating Epithelial Tumor Cells and Tumor Spheres

Circulating Epithelial Tumor Cells (CETC) and Tumor Spheres.

Discussion with Prof. Katharina Pachmann, Ph.D, M.D who is the medical Doctor in Jena University Hopital’s Department of Experimental Hematology and Oncology.  She is an expert on Circulating Epithelial Tumor Cells.
The role of CETC in monitoring cancer and its use for Chemo sensitivity was discussed.

A SUBPOPULATION AMONG CIRCULATING EPITHELIAL TUMOR CELLS IN PATIENTS WITH SOLID CANCER IS CAPABLE OF SPHERE FORMATION AND CARRIES CANCER STEM CELL PROPERTIES.

For more information Please visit www.maintrac.com

Or write to Info@PCREF.org

Posted in Cancer Stem Cells, CETC, CTC, Prognosis, Prostate Cancer, Treatments for Prostate Cancer, Tumor Spheres | Leave a comment

Prostvac Vaccination for Localized Prostate Cancer Disease

Prostvac in Preventing Disease Progression in Patients with Localized Cancer Undergoing Active Surveillance.

What is unique about  this vaccine study , is the fact that it is given to patients with localized disease.  Practically, the patient gets a series of vaccination injected under the skin.

Click here to send a video question and you will get an e mail video reply

Posted in Active Surveillance, Clinical Trials, Immune Therapy, Treatments for Prostate Cancer, Vaccine | Tagged , | Leave a comment

What is Liquid Biopsy- The Role of Exosomes

Liquid Biopsy – The Role of Exosomes. Dr. Israel Barken introduces the videos published by Life Technologies from ThermoFisher Technologies. The introduction relates to the importance of using imaging and markers to define recurrent disease and monitor the progression. The ability to harvest Tumor Cells, Free Tumor Cells DNA, MicroRNA from the blood, enables Genomic Interrogation of the tumor to assess prognosis, assist in follow up and create a personalized approach to the patient.

What is Exosome?

The History and Promise of Exosomes

Exosome in Cancer Research

 

 

 

Posted in Biomarker, CETC, CTC, Exosome, Genome, Imaging, Liquid Biopsy, Markers, Treatments for Prostate Cancer | Tagged | Leave a comment